Despite the group’s big losses since May, the results show Small/Micro Cap Biotechs are still richly valued. As market volatility heats up, this group faces additional downside risk.
Sep
09
2015
Small/Micro Cap Biotechnology: Still Richly Valued
Login
For full access, please enter your credentials.
Not a Subscriber?
If you are interested in subscribing to The Leuthold Group, contact us online or give us a call at 612-332-1567.
Contact UsAbout The Author
current issue
featured articles
recent tags
Bank Lending
(1)
Wealth Effect
(9)
Resession
(1)
Dollar
(55)
Inflation
(584)
Time Cycles
(6)
Oil
(48)
Breakeven Rate
(1)
Value
(130)
Treasuries
(79)
Long T-Bonds
(24)
Active vs. Passive
(17)
Yield Curve
(85)
Economy
(282)
Federal Spending
(2)
Stock Market Performance
(1)
Federal Debt/Deficit
(194)
Fed Policy
(173)
Federal Outlays
(1)
Stimulus
(4)